Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miwako Yomota

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cureus|September 25, 2023
Progressive Thymic Hyperplasia With Graves' Disease: A Case ReportNoriko Ogawa, Miwako Yomota, Masakazu Notsu, et al.
JMA Journal|November 12, 2025
Sex Differences in Renal Outcomes and Metabolic Markers by Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Individuals with Type 2 Diabetes: A Post-Hoc Analysis of the RECAP StudyYoshimi Muta, Kazuo Kobayashi, Masao Toyoda, et al.
Diabetes & Vascular Disease Research|December 14, 2023
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medicationKazuo Kobayashi, Masao Toyoda, Atsuhito Tone, et al.
Diabetes, Obesity & Metabolism|May 20, 2024
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease, Shunichiro Tsukamoto, Kazuo Kobayashi, et al.
Frontiers in Pharmacology|April 11, 2024
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP studyYoshimi Muta, Kazuo Kobayashi, Masao Toyoda, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cureus|September 25, 2023
Progressive Thymic Hyperplasia With Graves' Disease: A Case ReportNoriko Ogawa, Miwako Yomota, Masakazu Notsu, et al.
JMA Journal|November 12, 2025
Sex Differences in Renal Outcomes and Metabolic Markers by Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Individuals with Type 2 Diabetes: A Post-Hoc Analysis of the RECAP StudyYoshimi Muta, Kazuo Kobayashi, Masao Toyoda, et al.
Diabetes & Vascular Disease Research|December 14, 2023
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medicationKazuo Kobayashi, Masao Toyoda, Atsuhito Tone, et al.
Diabetes, Obesity & Metabolism|May 20, 2024
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease, Shunichiro Tsukamoto, Kazuo Kobayashi, et al.
Frontiers in Pharmacology|April 11, 2024
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP studyYoshimi Muta, Kazuo Kobayashi, Masao Toyoda, et al.
Pageof 1